Filing Flows › Alnylam Pharmaceuticals (ALNY) › Net income
Alnylam Pharmaceuticals (ALNY) net income by quarter
Alnylam Pharmaceuticals' net income was $2.2B in Q3 2026 (third quarter 2026), up 13-fold from Q2 2026. Over the last 4 quarters it ranged from $112M (Q4 2025) to $2.2B (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.2B | 13× | +763% |
| Q2 2026 | $164M | +47% | — |
| Q4 2025 | $112M | -56% | — |
| Q3 2025 | $251M | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' net income?
Alnylam Pharmaceuticals' net income was $2.2B in Q3 2026 (third quarter 2026), up 13-fold from Q2 2026.
How has Alnylam Pharmaceuticals' net income changed?
Over the last 4 quarters it ranged from $112M (Q4 2025) to $2.2B (Q3 2026).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →